Karyopharm Therapeutics Q4 2024 Earnings Preview

Karyopharm Therapeutics, trading on the NASDAQ under the ticker symbol KPTI, is set to release its earnings results for the fourth quarter of 2024 on Wednesday, February 19th, prior to the market opening.

Analysts are currently estimating that Karyopharm will report an earnings per share (EPS) of -$0.27. In terms of revenue, the consensus estimate stands at $35.67 million, which reflects a year-on-year growth of 5.8%.

Over the past three months, the EPS forecasts for Karyopharm have not seen any upward revisions, while there have been two downward adjustments. Similarly, revenue estimates have remained unchanged with two downward revisions noted.

Recent Developments at Karyopharm Therapeutics

Recently, Karyopharm announced preliminary revenue figures for 2024, indicating an evolving financial landscape for the company. In a significant corporate development, Lori Macomber has been appointed as the Chief Financial Officer (CFO). This leadership change may influence the company’s future financial strategies and outcomes.

Analyzing the Outlook for Karyopharm

As earnings approaches, analysts and investors are keenly watching Karyopharm’s performance. Seeking Alpha has provided a Quant Rating on Karyopharm Therapeutics, which may serve as a helpful tool for potential investors looking to gauge the company's financial health and performance trends.

A review of the historical earnings data for Karyopharm will also be beneficial in understanding how the company's earnings have shifted over time. This historical perspective can offer insights into the company’s operational stability and market position.

Karyopharm, earnings, preview